TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00399165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Oral Testosterone 400 mg orally for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Oral Testosterone 800 mg orally for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5 mg orally, once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5 mg orally, once daily for 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo sesame oil
Description: placebo sesame oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: 24.5 mg po once (Day 0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: 24.5 mg po once (Day 0)
Study: NCT01946607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02339493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Electronic Alert
Description: A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
Study: NCT04593654

Intervention type: DRUG
Intervention: Dose of tinzaparin or dalteparin
Description: The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Intervention type: DRUG
Intervention: Dose of tinzaparin or dalteparin
Description: The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Intervention type: DRUG
Intervention: Dose of tinzaparin or dalteparin
Description: The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
Study: NCT00023374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 6mos REZ intermittent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 6mos REZ intermittent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: 6mos REZ intermittent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REZ
Description: Rif+PZA+EMB given 2 or 3 times weekly for 6 months
Study: NCT03657251

Intervention type: GENETIC
Intervention: liquid biopsy
Description: Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
Study: NCT01570673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group urotherapy
Description: Children in this arm will receive group urotherapy in small groups with other children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Urotherapy
Description: Children will receive standard individual urotherapy in regular pediatric urology clinic.
Study: NCT01827033

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: meditation training
Study: NCT01353703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, three doses
Study: NCT02236052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted low dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted low dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted medium dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted medium dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted high dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted high dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted high dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study: NCT00096863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01787916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be compared to placebo for 24 weeks in a cross-over design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo will be compared to liraglutide for 24 weeks in a cross-over design
Study: NCT01090882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivocaine
Description: 20ml 0.25% at beginning of operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivocaine
Description: 20ml 0.25% at beginning of operation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9% normal saline solution
Description: 20ml 0.9% NaCl
Study: NCT03428165

Intervention type: OTHER
Group type: OTHER
Intervention: HCG
Description: 250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
Study: NCT00962832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a sterile liquid solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a sterile liquid solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rontalizumab
Description: Rontalizumab was supplied as a sterile liquid solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rontalizumab
Description: Rontalizumab was supplied as a sterile liquid solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rontalizumab
Description: Rontalizumab was supplied as a sterile liquid solution.
Study: NCT03881397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Media Use Plan
Description: A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Use Resources Awareness
Description: Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
Study: NCT03664999

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
Study: NCT03506243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follitrope PFS
Description: Follitrope PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f pen
Description: Gonal-f pen
Study: NCT00640328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 100
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 100
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300
Description: 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300
Description: 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700
Description: 700mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700
Description: 700mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT02278172

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 3000IU (75 μg) vitamin D in a commercially available oral spray solution

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral spray solution manufactured to mimic the vitamin D oral spray
Study: NCT04324372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC68498
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Study: NCT01666327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study: NCT01520571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Computer Assistance TKA
Description: Non-Computer Assistance Total Knee Arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Assistance TKA
Description: Computer Assistance Total Knee Arthroplasty
Study: NCT00357500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT02107586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps tenotomy
Description: A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biceps tenodesis
Description: Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
Study: NCT03733223

Intervention type: DRUG
Intervention: Ateptidase
Description: Treatment of ischemic stroke with Ateptidase

Intervention type: DRUG
Intervention: Ateptidase
Description: Treatment of ischemic stroke with Ateptidase
Study: NCT02425826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Apremilast
Description: At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Apremilast
Description: At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
Study: NCT02178488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol 4000 IU/day for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
Study: NCT03260959

Intervention type: BEHAVIORAL
Intervention: Interview by hierarchical evocation's Method
Description: Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
Study: NCT01464307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400 Units)
Description: Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
Study: NCT04000685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercise program
Description: Yoga exercise program will be applied two sessions per week, totally eight week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal stabilization exercise program
Description: Spinal stabilization exercise program will be applied two sessions per week, totally eight week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic walking program
Description: Aerobic walking program will be applied two sessions per week, totally eight week.
Study: NCT03475459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15 and/or Placebo
Description: The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
Study: NCT02065154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03650192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00027
Description: Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
Study: NCT02814630

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Xolair
Description: The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
Study: NCT00723164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Midazolam
Description: A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
Study: NCT03970902

Intervention type: OTHER
Intervention: Integrated Osteoporosis Care
Description: Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.

Intervention type: OTHER
Intervention: Care As Usual
Description: No intervention Patients receive care as usual from their family physician
Study: NCT02197676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 administration
Description: SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle.
Study: NCT05301946

Intervention type: OTHER
Intervention: Outcome Measurements
Description: The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
Study: NCT02418416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oocyte double chemical activation
Description: Oocyte double chemical activation
Study: NCT00737659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (CellCept® )
Description: Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (CellCept® )
Description: Fixed Dose group, MMF dosage will be adjusted based on standard care
Study: NCT02448407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Three intraarticular injections of platelet-rich plasma, one each fifteen days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
Study: NCT00356941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60 mg/m2 on day 1 of each week during radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 2 Gy Days 1-5 each week, total dose of 70Gy
Study: NCT01594021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelatin 500 mL
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin 50 mL
Description: intravenous administration
Study: NCT04824586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting human insulin
Description: Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting human insulin
Description: Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
Study: NCT02692209

Intervention type: DEVICE
Intervention: FFDM Plus DBT
Description: FFDM + DBT Images~FujiFilm Aspire Cristalle System

Intervention type: DEVICE
Intervention: FFDM Alone
Description: FFDM Alone Images
Study: NCT01687712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFOLIA
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f® RFF
Description: 225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
Study: NCT02987621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
Study: NCT02058680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA/IL-2/GM-CSF
Description: In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43.